

PLOS ONE

Supplemental data

**Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models
for *Mycobacterium tuberculosis* Drug Discovery**

Sean Ekins^{1,2*}, Peter B. Madrid^{3*}, Malabika Sarker³, Shao-Gang Li⁴, Nisha Mittal⁴, Xin Wang⁴,
Thomas P. Stratton⁴, Matthew Zimmerman,⁵ Carolyn Talcott³, Pauline Bourbon³, Mike Travers¹,
Maneesh Yadav³ and Joel S. Freundlich^{4*}

¹Collaborative Drug Discovery Inc., 1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, USA.

²Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA.

³SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA.

⁴Departments of Pharmacology & Physiology and Medicine, Center for Emerging and Reemerging Pathogens, Rutgers University – New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA.

⁵Public Health Research Institute, Rutgers University – New Jersey Medical School, Newark, NJ 07103, USA.

*Authors contributed equally; Addresses for correspondence: Sean Ekins, Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, CA 94010, USA. E-

mail:ekinssean@yahoo.com, Phone: 215-687-1320; Peter Madrid, SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA. E-mail: peter.madrid@sri.com; Joel S. Freundlich, Departments of Pharmacology & Physiology and Medicine, Center for Emerging and Reemerging Pathogens, Rutgers University – New Jersey Medical School, 185 South Orange Avenue Newark, NJ 07103, USA. E-mail: freundjs@rutgers.edu, Phone: 973-972-7165.

Figure S2. PCA with the TB mobile dataset showing the 3 hits in yellow – 88.8% of variance explained in 3 PCs.

